NASDAQ: MDCXMedicus Pharma Ltd Stock
$0.32-0.01 (-3.03%)
Updated Apr 24, 2026
MDCX Price
$0.32
Fair Value Price
$0.27
Market Cap
$12.40M
52 Week Low
$0.29
52 Week High
$8.94
P/E
-0.11x
P/B
-183.54x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$35.44M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-148.39
Operating Cash Flow
-$23M
Beta
0.88
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MDCX Overview
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MDCX's potential to beat the market
- MDCX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: General Drug Manufacturer
Industry Rating
A
MDCX
RankedUnranked of 17
RankedUnranked of 17
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $130.40 | A | |
| $58.71 | A | |
| $54.44 | B |
Be the first to know about important MDCX news, forecast changes, insider trades & much more!
MDCX News
Overview
Due Diligence Score
–
Industry Average (38)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MDCX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MDCX ($0.32) is overvalued by 15.6% relative to our estimate of its Fair Value price of $0.27 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MDCX ($0.32) is not significantly undervalued (15.6%) relative to our estimate of its Fair Value price of $0.27 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MDCX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MDCX due diligence checks available for Premium users.
Valuation
MDCX fair value
Fair Value of MDCX stock based on Discounted Cash Flow (DCF)
Price
$0.32
Fair Value
$0.27
Overvalued by
17.44%
MDCX ($0.32) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MDCX ($0.32) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MDCX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MDCX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.11x
Industry
31.86x
Market
35.58x
MDCX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-183.54x
Industry
6.65x
MDCX's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.2M
Profit Margin
0%
MDCX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$10.1M
Liabilities
$10.0M
Debt to equity
-148.39
MDCX's short-term liabilities ($9.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MDCX's short-term assets ($9.89M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MDCX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MDCX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.6M
Investing
$0.0
Financing
$6.7M
MDCX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MDCX vs General Drug Manufacturer Stocks
Medicus Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.